Regarding safety, the most common high-grade treatment-related adverse events (TRAE) for selpercatinib were high blood pressure (14%), elevated levels of alanine transaminase (ALT) (13%), and aspartate aminotransferase (AST) (10%), while neutropenia (18%), high blood pressure (11%), and anemia (10%) were common for pralsetinib. The gene discussed is GPT; the disease is Decreased total neutrophil count.